147688-62-8 Usage
General Description
2-phenyldihydro-2H-pyran-4(3H)-one is a chemical compound with the molecular formula C11H10O2. It is a white to off-white crystalline solid with a molecular weight of 174.2 g/mol. 2-phenyldihydro-2H-pyran-4(3H)-one is often used as a building block in the synthesis of various pharmaceuticals and natural products. It is also known for its potential applications in organic synthesis and medicinal chemistry. 2-phenyldihydro-2H-pyran-4(3H)-one has attracted attention for its diverse range of biological activities, including its potential as an antimicrobial, antifungal, and antitumor agent. Due to its versatile nature and potential pharmacological applications, this compound continues to be of interest to researchers in the fields of medicinal chemistry and drug discovery.
Check Digit Verification of cas no
The CAS Registry Mumber 147688-62-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,7,6,8 and 8 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 147688-62:
(8*1)+(7*4)+(6*7)+(5*6)+(4*8)+(3*8)+(2*6)+(1*2)=178
178 % 10 = 8
So 147688-62-8 is a valid CAS Registry Number.
InChI:InChI=1/C11H12O2/c12-10-6-7-13-11(8-10)9-4-2-1-3-5-9/h1-5,11H,6-8H2
147688-62-8Relevant articles and documents
A novel self-terminated Prins strategy for the synthesis of tetrahydropyran-4-one derivatives and their behaviour in Fisher indole synthesis
Reddy, B. V. Subba,Anjum, S. Rehana,Sridhar
, p. 75133 - 75137 (2016/08/24)
A novel self-terminated Prins strategy has been developed for the synthesis of 2-substituted tetrahydropyran-4-one derivatives through a condensation of 3-(phenylthio)but-3-en-1-ol with carbonyl compounds in the presence of 5 mol% of Sc(OTf)3 u
NOVEL PIPERIDINYL-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONES AS M1 AGONISTS
-
Page/Page column 36, (2009/11/29)
The present invention relates to novel M1 agonistic compounds of the present invention and their use in the treatment of cognitive impairment associated i.a. with schizophrenia and in the treatment of other diseases mediated by the muscarinic M1 receptor.